A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Sitagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 11 Oct 2017 Planned End Date changed from 28 Jan 2019 to 23 Jan 2020.
- 11 Oct 2017 Planned primary completion date changed from 28 Jan 2019 to 23 Jan 2020.
- 10 Jun 2017 Biomarkers information updated